JP2022516989A5 - - Google Patents
Info
- Publication number
- JP2022516989A5 JP2022516989A5 JP2021539972A JP2021539972A JP2022516989A5 JP 2022516989 A5 JP2022516989 A5 JP 2022516989A5 JP 2021539972 A JP2021539972 A JP 2021539972A JP 2021539972 A JP2021539972 A JP 2021539972A JP 2022516989 A5 JP2022516989 A5 JP 2022516989A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- composition according
- amount
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790229P | 2019-01-09 | 2019-01-09 | |
| US62/790,229 | 2019-01-09 | ||
| PCT/US2020/012649 WO2020146441A1 (en) | 2019-01-09 | 2020-01-08 | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516989A JP2022516989A (ja) | 2022-03-03 |
| JP2022516989A5 true JP2022516989A5 (cg-RX-API-DMAC7.html) | 2023-01-24 |
| JP7489989B2 JP7489989B2 (ja) | 2024-05-24 |
Family
ID=69500831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539972A Active JP7489989B2 (ja) | 2019-01-09 | 2020-01-08 | (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11779580B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908254A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7489989B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210113290A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114409630B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020206692B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3126067A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191904A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284665B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021008321A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202107438WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020146441A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2988714T3 (es) | 2020-07-07 | 2024-11-21 | Celgene Corp | Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas |
| KR20240013793A (ko) | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
| WO2025240252A1 (en) * | 2024-05-13 | 2025-11-20 | Beta Pharma, Inc. | Estrogen receptor degraders as treatments for breast cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| PY0323128A (es) * | 2002-09-10 | 2012-12-03 | Pharmacia Italia Spa | Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2604248B1 (en) * | 2011-12-13 | 2017-10-25 | Unilever PLC | Oil-in-water cosmetic composition |
| WO2014191806A2 (en) * | 2013-05-02 | 2014-12-04 | Effrx Pharmaceuticals Sa | Effervescent formulations that deliver particles which float in the stomach |
| UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| IL278854B2 (en) | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| EP3908582B1 (en) * | 2019-01-09 | 2025-11-12 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| DK3908281T3 (da) | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
-
2020
- 2020-01-08 AU AU2020206692A patent/AU2020206692B2/en active Active
- 2020-01-08 CN CN202210010518.8A patent/CN114409630B/zh active Active
- 2020-01-08 CA CA3126067A patent/CA3126067A1/en active Pending
- 2020-01-08 EP EP20704118.7A patent/EP3908254A1/en active Pending
- 2020-01-08 MX MX2021008321A patent/MX2021008321A/es unknown
- 2020-01-08 IL IL284665A patent/IL284665B1/en unknown
- 2020-01-08 US US16/737,721 patent/US11779580B2/en active Active
- 2020-01-08 WO PCT/US2020/012649 patent/WO2020146441A1/en not_active Ceased
- 2020-01-08 EA EA202191904A patent/EA202191904A1/ru unknown
- 2020-01-08 JP JP2021539972A patent/JP7489989B2/ja active Active
- 2020-01-08 CN CN202080012815.5A patent/CN113597301A/zh active Pending
- 2020-01-08 KR KR1020217024896A patent/KR20210113290A/ko active Pending
- 2020-01-08 SG SG11202107438WA patent/SG11202107438WA/en unknown
-
2023
- 2023-08-30 US US18/240,076 patent/US12064427B2/en active Active
-
2024
- 2024-07-09 US US18/767,295 patent/US20240358697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537772A (ja) | 新規egfr阻害剤 | |
| JP2021063088A5 (cg-RX-API-DMAC7.html) | ||
| AU2019391097B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| EP3630726B1 (en) | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| JP2022543155A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537158A5 (cg-RX-API-DMAC7.html) | ||
| RU2015151938A (ru) | Таблетируемый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью | |
| EA036098B1 (ru) | Способ получения противогрибковых соединений | |
| CN106458900A (zh) | 抗真菌化合物的制备方法 | |
| JP2022553954A5 (cg-RX-API-DMAC7.html) | ||
| JP6814886B2 (ja) | ベンゾイミダゾール誘導体を含む新規な製剤 | |
| JPH03151374A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| US11130740B2 (en) | Substituted 2,3-dihydro-1H-indene analogs and methods using same | |
| JP2022541938A5 (cg-RX-API-DMAC7.html) | ||
| CN115916750A (zh) | 用于制备具有经取代的苯基或吡啶基部分的serd三环化合物的方法 | |
| WO2002020539A1 (en) | Adenosine derivatives and use thereof | |
| HUP0001878A2 (hu) | (R)-3-(N,N-diciklobutil-amino)-8-fluor-3,4-dihidro-2H-1-benzopirán-5-karboxamid-hidrogén tartarát, eljárás előállítására és ezt tartalmazó gyógyszerkészítmények | |
| CA3099786A1 (en) | Crystalline form of s-apomorphine | |
| KR100830002B1 (ko) | 시부트라민의 무기산염 | |
| JP2016539994A (ja) | α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| JP2003055217A (ja) | 医薬組成物 | |
| US20240010641A1 (en) | N-Linked Glycosylation Inhibitors and Methods of Using Same | |
| JP2025532537A (ja) | Cd73阻害剤の医薬形態 | |
| JP2023533314A5 (cg-RX-API-DMAC7.html) | ||
| CN1353711A (zh) | 结晶性氮杂双环[2,2,2]辛烷-3-胺柠檬酸盐的多晶型物及其药物组合物 |